Article ID Journal Published Year Pages File Type
3978455 Bulletin du Cancer 2014 6 Pages PDF
Abstract
In phase II studies with CUP patients, BORR and the threshold of BORR > 30% for defining promising drug appears adequate.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials
Authors
, , ,